Intervention group (n = 30) | Control group (n = 30) | ||||
---|---|---|---|---|---|
n | % | n | % | ||
Age (years) | |||||
Mean (SD) | 61.3 (10.1) | 64.1 (10.9) | |||
Gender | |||||
Male | 14 | 46.7 | 19 | 63.3 | |
Female | 16 | 53.3 | 11 | 36.7 | |
Body Mass Index | |||||
Mean (SD) | 25.3 (4.5) | 24.4 (3.6) | |||
Karnofsky PS (median, range) | 80 (70-100) | 80 (70-100) | |||
Primary site | |||||
Lung | 12 | 9.2 | 8 | 26.6 | |
Breast | 5 | 16.7 | 6 | 20.1 | |
Prostate | 5 | 16.7 | 9 | 30.1 | |
Melanoma | 1 | 3.3 | 1 | 3.3 | |
Kidney | 1 | 3.3 | 2 | 6.7 | |
Other | 6 | 20.1 | 4 | 13.4 | |
Spinal metastases site | |||||
Thoracic | 17 | 56.7 | 14 | 46.7 | |
Lumbar | 9 | 30.0 | 13 | 43.3 | |
Thoracic and lumbar | 2 | 6.7 | 2 | 6.7 | |
Sacrum | 2 | 6.7 | 1 | 3.3 | |
Number of metastases | |||||
Mean (range) | 1.4 (2-4) | 1.7 (1-5) | |||
Solitary | 22 | 73.3 | 18 | 60.0 | |
Multiple | 8 | 26.7 | 12 | 40.0 | |
Type of metastases | |||||
Mixed | 2 | 6.7 | 2 | 6.7 | |
Osteoblast | 9 | 30.0 | 10 | 33.3 | |
Osteolytic | 19 | 63.3 | 18 | 60.0 | |
Concomitant metastases at baseline | |||||
Visceral | 12 | 40.0 | 5 | 16.7 | |
Brain | 3 | 10.0 | 3 | 10.0 | |
Lung | 7 | 23.3 | 4 | 13.3 | |
Tissue | 8 | 26.7 | 6 | 20.0 | |
Hormonotherapy | 10 | 33.3 | 16 | 53.3 | |
Immunotherapy | 7 | 23.3 | 5 | 16.7 | |
Chemotherapy | 25 | 83.3 | 20 | 66.7 | |
Pathological fracture at baseline | 6 | 20.0 | 9 | 30.0 | |
Neurological deficit | 0 | 0.0 | 2 | 6.7 |